Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Physiological Actions of GLP-1s

2023-09-11
|
Page View:

Physiological Actions of GLP-1s

GLP-1 shows numerous actions in different tissues and a broad therapeutic potential. The main actions of GLP-1 are to stimulate insulin secretion and to inhibit glucagon secretion, thereby contributing to limit postprandial glucose excursions. GLP-1 also causes weight loss by increasing satiety. In addition, GLP-1 also inhibits gastrointestinal motility and secretion and thus acts as an enterogastrone and part of the "ileal brake" mechanism.

GLP-1 New Drug R&D Service.webp

  • GLP-1 New Drug R&D Service

    Medicilon provides GLP-1 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, GLP-1 safety evaluation and other services. As of the end of May 2023, Medicilon has successfully assisted in the clinical approval of 7 GLP-1 drugs (3 approved by FDA and NMPA,1 approved by FDA, NMPA, and TGA) and has multiple GLP-1 projects under development.

Return
Relevant newsRelevant news